A new generation of melanoma researchers
15 February 2018
Melanoma impacts more Australian teenagers and young adults than any other cancer. Dr James Wilmott, who has a young family of his own, has devoted his career to determining why these young Australians are susceptible to melanoma, and importantly, how to save them.
James Wilmott is part of the new generation of melanoma researchers, and was drawn to Melanoma Institute Australia by the direct link between clinical research and patient care. He knew this was an area in which he could really make a difference.
“Being a scientist, you don’t often see patients in your day to day work,” he explains. “I thought by working at Melanoma Institute Australia, where it brings together clinical research and basic science, I could see patients as well as do the cutting edge research.”
Dr Wilmott’s work focuses on why 15 to 39 year olds are being diagnosed with melanoma at a higher rate than any other cancer. Early results of whole genome sequencing of tumours from these patients show 90% of all mutations in a 16 year old patient are caused by the sun – a surprising result given the young age of the patient.
“It is surprising because it looks similar to what we see in adults… and the accumulation over a lifetime,” Dr Wilmott says. “They must have some sort of genetic abnormalities that make them more susceptible to UV damage. If we can pinpoint the genes that make them susceptible, and then find them in other young patients, we can target them with preventative measures to prevent them from getting melanoma in the first place.
“It’s an exciting time to be involved in melanoma research. We’re making great inroads into melanoma care,” he said.
James’ is the latest in a series of emotive videos launched by Melanoma Institute Australia, showing the impact of melanoma on everyday Australians. Watch his story here and join him in the fight against melanoma by signing up for a Melanoma March event near you.
A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.
The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.
Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.
Professor Long cites as a highlight of her 2-year Presidency, the phenomenal research output by SMR members who have continued to lead the cancer field despite the impact of COVID-19.
Join in the fun of the virtual event, and together we can run over melanoma!
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.